BENTAMAPIMOD


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	XCPPIJCBCWUBNT-UHFFFAOYSA-N
Smiles	N#CC(c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1)c1nc2ccccc2s1
InChI	InChI=1S/C25H23N5O2S/c26-15-20(24-28-22-3-1-2-4-23(22)33-24)21-9-10-27-25(29-21)32-17-19-7-5-18(6-8-19)16-30-11-13-31-14-12-30/h1-10,20H,11-14,16-17H2

Mechanism of Action	Action	Reference
c-Jun N-terminal kinase, JNK inhibitor	INHIBITOR	PubMed


Protein: c-Jun N-terminal kinase, JNK Description: Mitogen-activated protein kinase 8 Organism : Homo sapiens P45983 ENSG00000107643











Protein: c-Jun N-terminal kinase, JNK Description: Mitogen-activated protein kinase 9 Organism : Homo sapiens P45984 ENSG00000050748

Assay Description	Organism	Bioactivity
Inhibition of JNK in human HeLa cells assessed as decrease in c-Jun activity at 10 uM after overnight incubation by dual luciferase reporter gene assay relative to control	Homo sapiens	50.0 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	78.42 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	6.398 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.12 %	Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.12 %

CONTENTS